Last edition
News about "NIDA funding"
Sparian Biosciences Begins Phase I Trial of Oral Pain Drug SBS-147 Targeting Opioid Alternatives
Sparian Biosciences advances SBS-147 into Phase I trials, aiming to develop a safer, non-opioid oral treatment for acute and chronic pain.
NIDA Funding | 11/04/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members